Biotech

All Articles

Actinogen's cortisol blocker neglects stage 2 depression study

.Actinogen Medical's cortisol blocker has overlooked the main endpoint of a stage 2 research study i...

Bivictrix chooses going personal only way to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have actually gone to the center of numerous a billion-dollar biobu...

TPG leadings up funds to $580M for assets throughout lifestyle scientific researches

.Possession manager TPG, which has assisted biotechs including Sionna Therapies as well as Santa Cla...

Merck quits phase 3 TIGIT test in lung cancer for futility

.Merck &amp Co.'s TIGIT system has actually gone through another obstacle. Months after shuttering a...

After a hard year, Exscientia folds up into Recursion

.After a year defined through pipeline cuts, the shift of its own CEO and also layoffs, Exscientia w...

Cullinan, after $25M offer, return bispecific to Harbour

.Cullinan Therapy was made an impression on good enough along with Harbour BioMed's bispecific immun...

A closer examine Fierce Biotech's Tough 15

.In this particular full week's incident of "The Best Pipe," our company're diving into Ferocious Bi...

Lilly encounters period 2 failure of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's celebration celebrating the commendation of...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of substantial leadership hirings, firings a...

Lykos will definitely talk to FDA to rethink its own selection observing turndown of MDMA treatment for trauma

.Adhering to an unsatisfactory revealing for Lykos Rehabs' MDMA prospect for post-traumatic stress d...